Indeed, the eIF4E/4E-BP ratio can predict efficacy of mTOR targeted therapies.36 Previously we reported that SBI-756 can fully suppress proliferation in 4E-BP1/4E-BP2 double knockout fibroblasts that are partially resistant to the TOR-KI compound Torin-1.19 To determine whether SBI-756-induced DLBCL death is 4E-BP-dependent, we used CRISPR/Cas9 genome editing to generate clones of OCI-LY1 cells lacking 4E-BP1 (Fig. S6). The gene discussed is RORC; the disease is diffuse large B-cell lymphoma.